top of page
AdobeStock_336920991_edited.jpg
Dr. Patricia Conrod

Unversité de Montréal, Quebec, Canada

Patricia Conrod is a Clinical Psychologist by training and a Full Professor of Psychiatry at the Université de Montréal. She is based at the CHU Sainte-Justine Mother and Child Hospital Research Centre in Montreal, where she holds a Tier 1 Canada Research Chair in Preventative Mental Health and Addiction, and a Research Chair in Social and Community Pediatrics funded by Fondation Julien/Jean & Marcelle Coutu. Her research focuses on cognitive, personality and biological risk factors for the development and maintenance of drug abuse and the factors that mediate the co-occurrence of addictive behaviours with other mental disorders. She developed the Preventure Program, which has been identified as an evidence-based prevention program in the UNODC International Standards for Drug Prevention and the U.S. Surgeon General’s 2016 Report on Addiction. Her research is funded by Canadian Institutes of Health Research, Fondation de Recherche en Santé du Quebec, European Commission (Health and Humanities and Social Sciences), National Institutes of Health, Medical Research Council-UK, National Health and Medical Research Council – Australia. She was a member of the CIHR Institute of Neurosciences Mental Health and Addiction Advisory Board (2012-2023), American College of Neuropsychopharmacology (2018-present) and Associate Editor of Neuropsychopharmacology. She has co-authored more than 200 peer reviewed articles. Her research has also been featured in news articles in the Financial Times, New York Times, The Guardian, Time Magazine, Maclean’s Magazine. Through the Preventure community of practice she trains professionals from around the world on evidence-based drug and alcohol prevention strategies. Dr. Conrod is Scientific Director of the FRQS Quebec Research Network on Suicide, Mood Disorders and Associated Conditions (RQSHA) and the CIHR Canadian Cannabis and Psychosis Research Team, and she leads the Strategy for Neuroscience and Mental Health at the Universite de Montreal (SENSUM; www.sensum.umontreal.ca). She is currently one of five panel members appointed by the Canadian Government to review the Cannabis Act, which will publish its recommendations in April, 2024.

bottom of page